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Development and formative evaluation of patient research partner involvement 1 
in a multi-disciplinary European translational research project 2 
 3 
Plain English summary 4 
Patient and public involvement (PPI) improves the quality of health research and 5 
ensures that research is relevant to patients’ needs. Though PPI is increasingly 6 
evident in clinical and health services research, there are few examples in the 7 
research literature of effective PPI in translational and laboratory-based research. In 8 
this paper, we describe the development and evaluation of PPI in a multi-centre 9 
European project (EuroTEAM – Towards Early biomarkers in Arthritis Management) 10 
that included both translational and laboratory-based and psychosocial research. We 11 
found that although most PPI in EuroTEAM was centred around the psychosocial 12 
research, there were examples of PPI in the laboratory studies. As the project 13 
evolved, researchers became better at accommodating PPI and identifying PPI 14 
opportunities. It was generally agreed that PPI had a positive impact on the project 15 
overall, particularly on public engagement with the research. We concluded that the 16 
inclusion of both psychosocial and laboratory-based research in the same project 17 
facilitated PPI across all aspects of the research. In future projects, we would try to 18 
specify individual PPI activities in more detail at the project-planning stage, and 19 
better accommodate patient partners who are not native speakers of English. 20 
 21 
Abstract  22 
Background: Patient and public involvement (PPI) enhances research quality and 23 
relevance and is central to contemporary health policy. The value of PPI has been 24 
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recognised in rheumatology research, though there are limited examples of PPI in 1 
basic and translational science. The EU FP7 funded ‘EuroTEAM’ (Towards Early 2 
biomarkers in Arthritis Management) project was established to develop biomarker-3 
based approaches to predict the future development of rheumatoid arthritis and 4 
incorporated psychosocial research to investigate the perceptions of ‘at risk’ 5 
individuals about predictive testing, and to develop informational resources about 6 
rheumatoid arthritis (RA) risk. Patient involvement was central to EuroTEAM from the 7 
inception of the project. The objective of this paper is to describe the development of 8 
PPI in EuroTEAM, formatively assess the impact of PPI from the perspectives of 9 
researchers and patient research partners (PRPs), reflect on successes and lessons 10 
learned, and formulate recommendations to guide future projects. 11 
Methods: Two mixed-methods surveys (for PRPs and researchers) and a 12 
teleconference were undertaken to assess the impact of PPI on individual work 13 
packages and on EuroTEAM overall.  14 
Results: There was consensus about the positive impact of PPI on the research and 15 
on the experiences of those involved. In particular, the positive impact of PPI on the 16 
personal development of researchers, and on effective public engagement with 17 
EuroTEAM research were highlighted. Researchers described adapting their practice 18 
in future projects to facilitate PPI. Spin-off projects and ongoing collaborations 19 
between PRPs and researchers reflected the value of PPI to participants. PPI was 20 
more frequently integrated in psychosocial research, though examples of PPI in 21 
laboratory/translational science were also described. PRPs asked for more 22 
opportunities to contribute meaningfully to basic scientific research and for more 23 
extensive feedback on their contributions. 24 
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Conclusions: The findings were used to formulate recommendations to guide 1 
effective involvement of patients in future similar projects, including identifying 2 
specific training requirements for PRPs and researchers, the identification of PRP 3 
focused tasks/deliverables at the project planning stage, and supporting access to 4 
involvement for all PRPs. Importantly, the distinctive multidisciplinary approach of 5 
EuroTEAM, incorporating both basic science and psychosocial research, facilitated 6 
patient involvement in the project overall. 7 
 8 
Keywords 9 
Patient and public involvement; evaluation; translational research. 10 
 11 
Background 12 
Patient-centred approaches are integral to contemporary health policy. 13 
Consequently, patient and public involvement (PPI) have become increasingly 14 
important in health research and service evaluation [1]. PPI has been defined as 15 
research being carried out “‘with’ or ‘by’ members of the public rather than ‘to’, 16 
‘about’ or ‘for’ them” [2]. It is a central theme of the National Institute for Health 17 
Research (NIHR) in the United Kingdom, and evidence of active engagement with 18 
PPI is now a requirement for many funding bodies, including the European Union’s 19 
Horizon 2020 (H2020) funding stream.  H2020 guidelines state that “Patients and 20 
citizens must be involved in the entire process, from the design of research 21 
programmes to the dissemination and implementation of results relating to wellbeing, 22 
health, social care, public health, and society” [3].  23 
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The involvement of patients in decisions that ultimately affect them has been 1 
accepted as beneficial to health research in a number of ways [4]. PPI enhances 2 
research quality, efficiency, and transparency, and helps ensure that public benefit is 3 
the key focus of the work undertaken.  Consultation with those affected by research 4 
outcomes has augmented research relevance and validity, and facilitated wider 5 
dissemination and engagement with research from patients / members of the public. 6 
Patients have become involved with delivering research goals in several ways, at all 7 
stages of the research process. For example, they have contributed to priority 8 
setting, supported grant applications, advised on clinical trial design, provided 9 
feedback on patient facing documents, prepared lay summaries and supported other 10 
forms of research dissemination. Patients’ experience of living with a disease has 11 
brought additional and unique perspectives [5].  12 
There has been a growing appreciation of the benefits of PPI within rheumatology 13 
research [6, 7].  For example, patients have contributed to:  the development of 14 
questionnaires to assess help-seeking behaviours in patients with new onset 15 
rheumatoid arthritis (RA) [8] and hypothetical reactions to the symptoms of RA 16 
amongst members of the public [9]; the development of interview schedules [10-12]; 17 
systematic reviews [13-15]; generating research ideas [16]; rheumatology 18 
conferences [17] and the development of international research recommendations 19 
[18-20].   20 
Effective PPI has fostered the development of ongoing, mutually advantageous 21 
relationships between researchers and patient research partners (PRPs) [21, 22]. 22 
However, maximising achievement of PPI goals has considerable resource 23 
implications. Funding may be required to compensate patients for their time and 24 
expenses, provide experienced staff to coordinate PPI and deliver appropriate 25 
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training for researchers and PRPs. Researchers need to invest time into the 1 
development of resources to support meaningful patient involvement, such as lay 2 
summaries, glossaries and background information on key project elements [23]. 3 
Without resource allocation to support PPI, patient involvement risks becoming 4 
tokenistic [24, 25].   5 
Whilst PPI has become increasingly commonplace in clinical and health services 6 
research, it has been less frequently integrated with early phase translational and 7 
laboratory based research [26, 27]. Although patients and researchers agree on the 8 
benefits of PPI in pre-clinical translational research in the context of rheumatology, 9 
associated challenges include communication between researchers and patients 10 
about scientific concepts and terminology and limited access to and awareness of 11 
PPI opportunities [28-30].   12 
A further challenge associated with PPI is the difficulty in evaluating its impact [23]. 13 
Whilst there have been calls for more robust quantitative assessment of the impact 14 
of PPI on research quality, it has been argued that it is also important to capture the 15 
experiential, contextual impact of PPI on both researchers and patient research 16 
partners [31]. 17 
This paper describes the development and formative evaluation of the impact of PPI 18 
in a European Union FP7 funded translational research project, EuroTEAM - 19 
Towards Early biomarkers in Arthritis Management, which ran from 2012 to 2016.  20 
The aim of this multidisciplinary project was to develop new biomarker-based 21 
approaches to predict the development of RA in people who do not yet have the 22 
disease. RA is a chronic inflammatory disease affecting the joints and internal 23 
organs, and is associated with a reduced life expectancy of around 10 years.   Early 24 
treatment of RA is associated with better clinical outcomes. If uncontrolled, this 25 
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painful condition can lead to irreversible joint erosion and disability [44]. Improved 1 
prediction of RA development would facilitate early treatment and the development 2 
of preventive interventions.  3 
An innovative aspect of the EuroTEAM project was that it encompassed both 4 
laboratory based science that addressed the identification of predictive biomarkers 5 
[32-38] and psychosocial research, that explored the perspectives of potential end-6 
users of predictive tests for RA, and how disease related risk information could be 7 
communicated effectively to those at risk of developing RA in the future [39-43]. In 8 
order to ensure the quality and relevance of the research and to facilitate effective 9 
translation and dissemination of the research findings, PPI was considered an 10 
essential part of EuroTEAM from its inception. PPI was specifically funded and 11 
supported by the management team. 12 
The objective of this paper is to describe the development of PPI in the EuroTEAM 13 
project, and the results of two mixed-methods surveys, undertaken towards the end 14 
of the project to capture the perspectives of both researchers and patients on the 15 
impact of PPI on this research. Our secondary objective is to reflect on the findings 16 
of this evaluation to identify good practice and areas for improvement to inform 17 
effective PPI in future projects of this kind. 18 
 19 
Methods 20 
Patient research partner involvement and EuroTEAM 21 
The EuroTEAM project was a multidisciplinary collaboration between 16 partners 22 
across Europe [Table 1a]. The consortium comprised of 13 universities and 3 23 
small/medium enterprises (SMEs) led by the University of Birmingham.  EuroTEAM 24 
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contained 5 work packages (WPs): genetic biomarkers (WP1), blood biomarkers 1 
(WP2), tissue biomarkers (WP3), dissemination and user integration (WP4), and 2 
project management (WP5).  WPs 1-3 comprised of laboratory-based studies to 3 
identify biomarkers predictive of future RA development.  The focus of WP4 was 4 
psychosocial research to elucidate the perspectives of individuals with an elevated 5 
risk of developing RA in the future (first degree relatives of existing RA patients and 6 
individuals with clinically suspect joint symptoms) [45]. The aim was to capture this 7 
group’s thoughts about being ‘at risk’, their acceptance of predictive testing and 8 
preferences for risk communication. A further objective of WP4 was the development 9 
and evaluation of informational material for individuals at risk of developing RA. 10 
During the early planning stages of EuroTEAM, several national RA organisations 11 
and patient groups in a range of European countries [Table 2] were approached in 12 
order to seek endorsement of the project, provide advice and support for the funding 13 
application, and to identify potential PRPs. Additional PRPs were recruited via 14 
clinician researchers and PRPs’ own networks, resulting in a panel of 9 PRPs; 8 15 
patients with a diagnosis of RA and 1 person whose first-degree relative had RA 16 
[Table 1b]. PRP activity was co-ordinated by a research group manager and PRPs 17 
were compensated for travel/subsistence expenses incurred.  18 
PRPs contributed to a number of research activities over the 4 year project, with 19 
participation being voluntary at all times.  Research activities with active patient 20 
partner involvement included: 21 
 Attending and contributing to annual scientific meetings and regular 22 
teleconferences 23 
 Development of a glossary resource (WP1-4) 24 
10 
 
 Contributing to a meta-synthesis of qualitative literature on public perceptions of 1 
predictive testing [13, 14] (WP4) 2 
 Contributing to the development of interview schedules (including question 3 
setting) and the interpretation of qualitative data [12, 46] (WP4) 4 
 Contributing to the development of informational resources for those at risk 5 
(WP4) 6 
 Evaluating a web-based platform for the communication of risk information (WP4) 7 
 Developing a questionnaire for patients undergoing a lymph node biopsy 8 
procedure (WP3) 9 
 Developing informational resources for patients about RA such as the ‘Metaphor 10 
Project’ (a collaboration between Eva C Johansson (PRP) and Dr Heidi 11 
Wähämaa from the Karolinska Institutet) exploring the communication of scientific 12 
concepts via the use of metaphors and visual representations 13 
 Contributing to the project website (e.g. providing news items and reports, 14 
creating subtitles for videos) (WP4) 15 
 Developing lay summaries of EuroTEAM methods and findings (e.g. lay summary 16 
of metabolomics in EuroTEAM) (WP2) 17 
 Developing posters for dissemination at the European League Against 18 
Rheumatism (EULAR) Congress (WP1-4) 19 
Training for PRPs was provided on an ad-hoc basis for specific research activities 20 
(e.g. analysis and interpretation of qualitative data) [14]. Annual project meetings 21 
included a day focused specifically on PRPs, where presentations were delivered by 22 
the researchers in lay language.  No formal training for researchers was provided, 23 
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however EULAR patient involvement reference cards were utilised by some 1 
consortium members [47].  Many researchers adapted to accommodate PRP needs 2 
as the project evolved, due to increased mutual understanding. For example, lay 3 
summaries were incorporated into research presentations, and frequent short breaks 4 
were introduced at annual meetings to avoid PRPs sitting for long periods. 5 
 6 
Evaluation of PPI in EuroTEAM 7 
Towards the end of the EuroTEAM project, two surveys (one for PRPs and another 8 
for researchers; Additional Files 1 and 2, respectively) were developed to evaluate 9 
the impact of PPI in EuroTEAM. The surveys included Likert-type response scales 10 
and free text responses and asked respondents to evaluate the impact of PPI in 11 
WPs1-3 and WP4 separately, as well as the impact of PPI on the project as a whole. 12 
The design and content of the surveys themselves were developed in collaboration 13 
with PRPs to ensure they were understandable and comprehensive. The surveys 14 
were distributed in April 2016 via email to all 9 PRPs and 51 researchers [Table 3]. 15 
Email reminders were sent out to non-responders after 2 weeks. Responses were 16 
collated and summarised descriptively. The frequency with which each response 17 
category was chosen was summed for Likert-type scales, and descriptive thematic 18 
analysis of free text responses was undertaken by RB and MF. A teleconference 19 
was held with PRPs and researchers to review and interpret the survey findings and 20 
their implications for future projects. Two PRPs also contributed to the preparation of 21 
this manuscript. 22 
 23 
 24 
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Results 1 
Respondents 2 
Sixty-six per cent (6 out of 9) of PRPs and 29% (15 out of 51) of researchers 3 
completed the surveys. All the PRPs who responded were female. Two were aged 4 
between 30-39 years, two aged 50-59 years and two were aged between 60-69 5 
years. 6 
Eleven of the 15 researchers were female. Four were aged between 30-39 years, 7 
eight were aged 40-49 years, two were 50-59 years and one was aged between 60-8 
69 years). Fourteen were from academic institutions, one was from an SME. Six 9 
were clinical researchers, nine were non-clinical researchers.  10 
Survey for patient research partners 11 
The quantitative results of the survey for PRPs are summarized in Table 4. All of the 12 
PRP respondents reported that their involvement had a positive overall impact on the 13 
EuroTEAM project. This was mainly described in terms of the effect of their 14 
involvement on researchers’ perspectives and ability to communicate with members 15 
of the public: 16 
“A present, physical reminder of the lay aspects of communication and the 17 
patient perspective.” 18 
Respondents stated they had made a large or moderate positive contribution to 19 
WP4, and described being involved in specific research activities: 20 
“Contribution at coding and summarizing activity, study protocol, 21 
leaflet/brochures for patients, dissemination (in the future), feedback 22 
questionnaires, video transcript, writing an article in PARE [People with 23 
Arthritis/Rheumatism in Europe)] e-Breakthrough, EuroTEAM website” 24 
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The majority of the PRPs thought they had made a minor or moderate positive 1 
contribution to WPs 1-3, with one PRP reporting a larger contribution  2 
“I think we made a large contribution to the lymph node biopsy 3 
questionnaire for WP3, but for WP1 and WP2 maybe not so much, apart 4 
from the overall impact.”  5 
Most of the PRPs found they had a moderate understanding of EuroTEAM from the 6 
outset. Half of the PRPs said there were about the right number of assignments for 7 
them, whereas half stated that there were too few assignments. All agreed that the 8 
assignments were of an appropriate level of difficulty and that they received suitable 9 
levels of information about them, however some respondents mentioned that more 10 
contextual information or specific training and feedback would have been useful. Half 11 
of the respondents stated that they had received too little feedback on the outcome 12 
of their contributions to this project: 13 
“When introducing a completely new skill – e.g. coding – perhaps more 14 
training, and feedback, would be helpful” 15 
All respondents agreed that the glossary resource was either very useful or 16 
extremely useful, and that PRP involvement in EuroTEAM was well co-ordinated.  17 
PRP contributions were reported to have been welcomed by researchers and fairly 18 
acknowledged: 19 
“We were welcomed and included in the team. We were listened to with 20 
respect. We were included in setting recommendations for future work.” 21 
Most PRPs mentioned that their contribution to meetings was very or extremely well 22 
supported, although one reported that there had been a moderate amount of 23 
support.  Some described how this support evolved over the project: 24 
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“By the end of the project, with PRPs in the room, the researchers 1 
automatically featured some lay language in their presentations, avoiding 2 
the need for separate briefing: by this stage the PRPs themselves were 3 
also more familiar with the scientific concepts and language of the project. 4 
So we all learnt together.” 5 
For many respondents, building relationships with researchers was one of the most 6 
valuable aspects of participating in EuroTEAM: 7 
“Enjoyed opportunity to talk to researchers and especially encouraging 8 
young researchers to interact with patients.” 9 
In particular, PRPs valued being treated as respected equal partners in the research 10 
process… 11 
“Never felt patronised but always valued.” 12 
… and found that their involvement with EuroTEAM had had a positive impact on 13 
them personally: 14 
“A definite positive impact. Very informative and challenging in a good 15 
way. I’ve definitely grown as a person through the work and meeting all 16 
the people in the consortium”. 17 
Such interactions between researchers and PRPs also led to the development of 18 
innovative spin-off collaborations: 19 
“The Metaphor project showed pure imagination.” 20 
All respondents to the survey for PRPs were either very interested or extremely 21 
interested in contributing to future projects as a PRP. When asked how PRP 22 
involvement could have been improved in EuroTEAM, some described accessibility 23 
15 
 
issues relating to accommodation provided at annual project meetings, and several 1 
made suggestions to support communication between researchers and PRPs, such 2 
as: the need for short breaks during meetings; more materials in lay language; more 3 
feedback on project progress and the outcome of PRPs contributions; lay summaries 4 
and printouts of slides used in presentations; consideration of non-native English 5 
speakers’ needs during teleconferences and face to face meetings  6 
Some also identified missed opportunities for dissemination: 7 
“I think the PRPs themselves could have written (or should write) an 8 
abstract about their experiences and submit it for the PARE sessions at 9 
the EULAR congress.” 10 
Survey for researchers 11 
The quantitative results of the survey for researchers are summarised in Table 5. 12 
Respondents had varying levels of previous experience of working with PRPs, 13 
ranging from none to extensive experience, however the majority of researchers 14 
reported no prior experience. All respondents were in agreement that PRP 15 
involvement had a positive impact on EuroTEAM: 16 
“The patient research partners have not only given an insight into what it 17 
actually entails to have RA and which aspects they feel we need to 18 
address in our research, they have contributed enormously to the project, 19 
both intellectually and practically. It has made the project’s outcomes 20 
more valuable to the RA community, relatives and friends as well as the 21 
research community.” (non-clinical researcher, academic institution) 22 
“The respect which was shown for PRPs (for example, mini pauses) 23 
created an overall kind and positive atmosphere. PRP presence reminds 24 
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us why we do research. For non-clinical scientists it is really important to 1 
meet patients – for some scientists EuroTEAM might have been the first 2 
time?” (non-clinical researcher, academic institution) 3 
Several researchers recounted that they had learnt a great deal from their 4 
involvement with PRPs, particularly in relation to their ability to engage with the 5 
public about their research:  6 
“I personally learned a lot about how to translate scientific terminology into 7 
understandable language to meet the demands of a lay audience.  It was 8 
advantageous for the project that the patient focus sometimes differed 9 
from the scientific/medical focus.” (communications manager, SME) 10 
Of the five respondents who were most involved in WP2, one mentioned that PRPs 11 
had not been able to contribute positively to this work package: 12 
“The PRPs were very interested in our research, but did not/could not 13 
contribute to the research questions, methods or interpretation of the 14 
results.” (clinical researcher, academic institution) 15 
Another said that PRPs had been able to make a minor contribution, whereas 16 
another stated that PRPs had contributed moderately and two found that PRPs had 17 
been able to make a large contribution to this work package. 18 
Of the four respondents who were most involved in WP3, one found that the PRPs 19 
had not been able to contribute positively, others stated that PRPs had made a 20 
minor (N=1) or large (N=2) contribution to this work package. 21 
Amongst the six respondents who were most involved in WP4, there was 22 
agreement that PRPs had been able to make a large (N=3) or extremely large 23 
(N=3) contribution: 24 
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“Their contribution has been very substantial … They have been involved 1 
with the coding and analysis of interviews. They have been an integral 2 
part of the development of the resources for people at risk of RA. PRPs 3 
have been instrumental in the development of the information resources 4 
we developed for people at risk of RA.” (non-clinical researcher, academic 5 
institution) 6 
Five of the 15 researchers had been involved in more than one work package. Two 7 
of these had additionally been involved in WP1, and reported that PRPs had not 8 
been able to make a positive contribution at all, two had also been involved in WP3 9 
and reported that PRPs had made a minor or moderate contribution. One researcher 10 
had additional involvement in WP4 and reported that PRPs had made an extremely 11 
large contribution to that work package. 12 
The majority of PRP involvement was perceived to be focused around the 13 
psychosocial research carried out in WP4 and researchers sometimes found it 14 
difficult to identify meaningful ways to involve patients in other work packages:  15 
“All work packages and research projects should have had input from 16 
PRPs and perhaps this should have been implemented earlier on. It 17 
should be an integral part of all the research carried out from the very 18 
beginning. In some of the more basic research this might be difficult on a 19 
practical level, but lay summaries of the findings at various stages are a 20 
minimum.” (non-clinical researcher, academic institution) 21 
Those who actively involved PRPs found it very rewarding. For example: 22 
“I had direct talks with patients followed by email correspondence in 23 
developing lay summaries of technologies. These were overwhelmingly 24 
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positive, with positive involvement of the patients and a good and 1 
worthwhile contribution to the refinement of informational sources.” (non-2 
clinical researcher, academic institution) 3 
“Close involvement with the partners with producing lay summary of 4 
metabolomics technologies to augment a broader understanding.” (non-5 
clinical researcher, academic institution) 6 
When asked how PRP involvement in EuroTEAM had affected how they would 7 
involve PRPs in future projects, several researchers indicated that their perception of 8 
PPI had evolved throughout the project:  9 
“Before working on EuroTEAM I was always somewhat wary of the idea of 10 
working with patients on research – I worried that they wouldn’t 11 
understand our work and that their direction would move research away 12 
from basic science to outcomes that aren’t the sort of thing I can do. 13 
However, I was mistaken. They are brilliant, enthusiastic and very 14 
supportive!” (non-clinical researcher, academic institution) 15 
In addition, it was mentioned that PRPs could have a greater role in setting the 16 
research agenda: 17 
“It would have been interesting to hear what individual PRPs think about 18 
the ongoing research and get their input on which kind of research they 19 
think we should prioritise and focus on. This would increase our insights 20 
(especially non-clinical researchers) what RA patients experience as a 21 
big health issues affecting their daily life.” (non-clinical researcher, 22 
academic institution) 23 
19 
 
Others described gaining insight that would change their approach in future projects, 1 
and highlighted that they would endeavour to find more meaningful ways for PRPs to 2 
be involved in basic scientific research: 3 
“I would be more proactive in identifying tasks for PRPs to get involved 4 
with in the context of biological research studies to allow for their better 5 
integration into these projects.” (clinical researcher, academic institution) 6 
“Try to find ways of asking for very specific, as well as general feedback 7 
on research.” (non-clinical researcher, academic institution) 8 
It was also suggested that facilitating small-scale meetings alongside annual 9 
project meetings might facilitate communication between researchers and 10 
PRPs: 11 
“Discussions on a personal level with PRPs present at the annual meeting 12 
happened during coffee/lunch breaks or dinner. Sometimes it was a bit 13 
hard to start a conversation and for the junior researchers it might not 14 
always have been clear, who the PRPs were and what they could talk 15 
about. Maybe this could be more guided somehow. Maybe by introducing 16 
a kind of speed date session for researchers and PRPs at the start of the 17 
project? Guided by the EULAR reference cards?” (non-clinical researcher, 18 
academic institution) 19 
Some researchers believed that PPI should be incorporated into basic training 20 
for all researchers: 21 
“I think that PRPs could (should?) be included as part of the PhD 22 
education: 23 
- To practice how to communicate with lay people 24 
20 
 
- To meet a “real patient”, not only working with patient samples”  1 
(non-clinical researcher, academic institution) 2 
Some researchers mentioned that as a direct result of their positive experiences of 3 
working with PRPs in EuroTEAM, they had gone on to include PRPs in other 4 
projects: 5 
 “From EuroTEAM we recruited our “own” PRP to our research group… 6 
Overall, she has been a very important link between our rheumatologists 7 
and non-clinical PhD students and post-docs... Our group meetings are 8 
not only about cells and molecules anymore, we have also patient-9 
orientated discussions with our rheumatologists.” (non-clinical researcher, 10 
academic institution) 11 
“The involvement of PRPs was very important for my personal 12 
development. In the past I had no idea on how to contact them (as a non-13 
clinical researcher) and how we could together bring research to a higher 14 
level. For me a new door has opened, and currently I am in contact with 15 
PRPs to discuss my future research proposal.” (non-clinical researcher, 16 
academic institution) 17 
 18 
Discussion 19 
These findings demonstrate the positive impact of PPI on a multi-centre, 20 
multidisciplinary European translational research project that incorporated both 21 
laboratory/translational science and psychosocial research. PRPs and researchers 22 
who completed the surveys reported that the involvement of PRPs in the project 23 
enhanced the research and their own experience of participating in this project. Both 24 
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groups described the value of building ongoing relationships between patients and 1 
researchers and interactively developing their own knowledge and communication 2 
skills in ways that were not only personally rewarding but also facilitated effective 3 
public engagement and dissemination of the research findings. The development of 4 
innovative spin-off projects and ongoing future collaborations between PRPs and 5 
researchers reflected the value of PPI to those involved.  6 
There was agreement between all respondents that the PRPs were able to make 7 
significant positive contributions to the psychosocial research and dissemination 8 
activities associated with WP4, but several reported that PRPs were less able to 9 
make a meaningful contribution to the laboratory-based research undertaken in 10 
WPs1-3. However, there were examples of effective patient contributions to these 11 
work packages that were valued by researchers and PRPs, such as the 12 
development of a questionnaire for patients undergoing a lymph node biopsy 13 
procedure, lay summaries of metabolomics studies, and lay posters of EuroTEAM 14 
findings, which were presented at the European League against Rheumatism 15 
(EULAR) Annual Meeting 2016. Several researchers mentioned that in future, they 16 
would actively try to identify specific (rather than general) ways in which patients 17 
could contribute to laboratory-based projects and dissemination of project results. It 18 
is possible that laboratory-based researchers’ awareness of PPI and confidence to 19 
implement it in their own research increased in response to proximity with the PPI 20 
activity that developed in WP4. In this respect, the distinctive multidisciplinary 21 
structure of EuroTEAM facilitated the evolution of PPI in this project. Moving towards 22 
more integrative, interdisciplinary models may further enhance PPI by developing 23 
common ground that is conducive to collaboration between patients and 24 
researchers. 25 
22 
 
The challenges associated with the involvement of patients in early stage 1 
translational science could be at least partly be addressed by appropriate training for 2 
researchers about the benefits of PPI and how to identify opportunities and 3 
overcome barriers to useful PRP involvement. This could be further supported at the 4 
project planning stage by incorporation of deliverables and/or milestones that 5 
specifically relate to activities involving PRPs, such as the development of lay 6 
progress reports. However, it may be difficult to specify in advance the extent to 7 
which patients are able or willing to be involved. It is important to avoid imposing 8 
heavy workloads or tight deadlines on patients who may have limited availability and 9 
are continuously managing the impact of a chronic condition on their lives, which 10 
may also be busy with work, family or other commitments. It is important that 11 
patients do not feel pressurised to contribute to research activities unwillingly in order 12 
to satisfy research objectives or funders’ requirements. 13 
A further issue raised was that PRPs thought that they would have benefitted from 14 
more direct feedback on the outcome or impact of their contributions to research 15 
activities, and ongoing progress of research studies within the project. Researchers 16 
may not always have been aware of the extent to which feedback could be provided 17 
to PRPs, or have had the time needed to provide such feedback. These findings 18 
align with recent work to clarify the kinds of feedback needed by public contributors 19 
to research. [48]These issues could also be addressed, in collaboration with PRPs, 20 
at the project planning stage. Training may be required (for both researchers and 21 
PRPs) and resources allocated to support the development of effective PPI, 22 
especially where local or institutional infrastructure or funding to support such 23 
activities is insufficient or absent. It was suggested in the current evaluation and 24 
elsewhere [28] that PPI related training could be integrated into basic training for 25 
23 
 
research students. It is not difficult to imagine that funding bodies will increasingly 1 
expect institutional infrastructure, as well as project-specific capacity to support such 2 
PPI facilitators to be demonstrated, to ensure research relevance and impact. 3 
 4 
Strengths and limitations 5 
A strength of the surveys described here was the use of both quantitative and 6 
qualitative methods,  which facilitated formative empirical assessment of the impact 7 
of PPI on the EuroTEAM project, and captured the experiential and contextual 8 
impact from the perspectives of the researchers and PRPs involved. The impact of 9 
PPI can be framed in terms of impact on the research itself or impact on the 10 
stakeholders involved [31, 49]. For example, some of the researchers in the present 11 
survey described how they had gained knowledge about RA from the patients’ 12 
expertise, and how they would alter their practice to facilitate PPI and dissemination 13 
in future projects as a direct result of their participation in EuroTEAM. 14 
A second strength of the surveys was that they were developed in collaboration with 15 
PRPs, to ensure that the questions included were comprehensive from their 16 
perspective. PRPs also contributed to the interpretation of the survey results and the 17 
preparation of this manuscript, ensuring that their viewpoints were fully and fairly 18 
represented. A further strength was the pan-European nature of both PRPs and 19 
researchers. 20 
A limitation of the surveys was that the respondents are unlikely to be representative. 21 
PRPs were mostly active members of patient organisations and therefore fully 22 
engaged with the promotion of patient representation and involvement. However, this 23 
can be said of most patients who are actively involved in research and is not specific 24 
24 
 
to this study. Not all PRPs/researchers responded to the survey, and the response 1 
rate was particularly low amongst researchers, despite email reminders. With low 2 
participant numbers, the utility of the quantitative approach beyond formative 3 
evaluation was limited. Furthermore, as surveys were returned via email, 4 
respondents were identifiable. It is therefore possible that the results were 5 
susceptible to social desirability bias, or that those who responded were more likely 6 
to be proactively engaged with PPI and favourable towards the involvement of PRPs 7 
in a project of this kind.  8 
The notion of representativeness of PRPs is a matter of ongoing debate [50].  Self-9 
selected patient representatives often develop considerable research expertise in 10 
their own right, and this empowers them to contribute meaningfully to the research 11 
process. However, this could also be considered to detract from their position as 12 
representatives of the experience of lay people [28].  Ensuring that patients from all 13 
social groups have equal access to PPI is challenging, and the ability of patients at 14 
different stages of a disease to participate is likely to be variable, though they may 15 
have very different perspectives on research priorities.   16 
We conducted this formative evaluation of PPI towards the end of the project, but 17 
note that PPI practice adapted throughout in response to PRPs needs and feedback 18 
on specific elements, such as annual scientific meetings. More formal, iterative 19 
assessment of PRP satisfaction throughout the project lifecycle could have 20 
supported this adaptive process [28]. 21 
 22 
Conclusions and recommendations 23 
25 
 
There was consensus among PRPs and researchers about the positive impact of 1 
PPI on EuroTEAM. These findings suggest that PPI can be usefully incorporated in 2 
future projects of this kind, and that barriers and facilitators to the implementation of 3 
effective PPI in this context should be identified and addressed. On the basis of 4 
these findings, it is possible to make the following recommendations, which we hope 5 
will guide future projects: 6 
 Initiatives to support communication between researchers and patients, such 7 
as glossaries and advance lay summaries of research presentations were 8 
highly valued and could usefully be incorporated and further developed in 9 
future projects. 10 
 The unusual multidisciplinary structure of EuroTEAM facilitated patient 11 
involvement in the project overall. Further research is needed to define the 12 
ways in which multi- and interdisciplinary research can enhance PPI. 13 
 Additional training would have been useful for both researchers and PRPs to 14 
support effective PPI and the development of mutually advantageous 15 
relationships. For example, identification of opportunities for meaningful PPI, 16 
awareness of PRP needs, providing feedback and developing communication 17 
skills. 18 
 It would have been useful to identify specific tasks/areas for development with 19 
PRPs at the project planning stage and to consider including such activities as 20 
deliverables/milestones where feasible. 21 
 Regular opportunities for feedback on the impact of PRPs contribution to 22 
specific research activities, and on the progress of the project overall, was 23 
26 
 
highly valued, and could also have been specified at the project planning 1 
stage.  2 
 Equality of access to patient representation could have been addressed more 3 
effectively, both when planning PRP recruitment and throughout the project; 4 
for example by facilitating awareness and access to PPI to all patients, not 5 
just those who are active members of patient organisations; providing 6 
translation services and support for non-native speakers; and supporting 7 
research involvement for individuals with particular literacy or mobility/access 8 
needs.   9 
 10 
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Table 1. Geographical distribution of EuroTEAM a) consortium partners and b) 1 
patient research partners (PRPs). 2 
a) EuroTEAM consortium partner organizations: 
Country Number of organizations 
Austria (Medical University of Vienna) 1 
Germany (Charité, Universitätsklinikum Erlangen, 
Orgentec) 
3 
Iceland (deCODE) 1 
The Netherlands (LUMC, AMC, Arthrogen) 3 
Sweden (Karolinska Institutet, KTH, Uppsala 
Universitet) 
3 
Switzerland (University of Zurich) 1 
United Kingdom (University of Birmingham, 
University of Leeds, University of Glasgow, 
University of Manchester) 
4 
  
b) EuroTEAM PRPs:  
Country Number of PRPs 
Estonia 1 
Germany 1 
The Netherlands 1 
Romania 2 
Sweden 1 
United Kingdom 3 
 3 
 4 
 5 
 6 
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Table 2. European patient organisations approached to identify potential 1 
patient research partners 2 
Organisation Website 
Swedish Rheumatism Association www.reumatikerforbundet.org  
National Rheumatoid Arthritis Society (UK) www.nras.org.uk  
Deutsche Rheuma-Liga www.rheuma-liga-berlin.de  
Reuma patiënten vereniging Leiden (Netherlands) home.reumafonds.nl  
EULAR - PARE (European League Against 
Rheumatism - People with Arthritis / Rheumatism 
across Europe) 
www.eular.org/pare.cfm  
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
42 
 
Table 3. Survey recipients 1 
a) EuroTEAM researchers: 
Country Number of researchers 
who received the survey 
Austria (Medical University of Vienna) 4 
Germany (Charité, Universitätsklinikum Erlangen, 
Orgentec) 
7 
Iceland (deCODE) 1 
The Netherlands (LUMC, AMC, Arthrogen) 8 
Sweden (Karolinska Institutet, KTH, Uppsala 
Universitet) 
7 
Switzerland (University of Zurich) 4 
United Kingdom (University of Birmingham, 
University of Leeds, University of Glasgow, 
University of Manchester) 
20 
  
b) EuroTEAM PRPs:  
Country Number of PRPs who 
received the survey 
Estonia 1 
Germany 1 
The Netherlands 1 
Romania 2 
Sweden 1 
United Kingdom 3 
 2 
 3 
 4 
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Table 4. Quantitative results of the survey for patient research partners (PRPs; 1 
N=6). 2 
 
Q1. What kind of impact has PRP involvement had on EuroTEAM overall? 
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Q2. How much do you feel you have been able to contribute positively to WPs 1-
3? (WP1 genetics, WP2 blood, WP3 tissue) 
 
 N
o
 
c
o
n
tr
ib
u
ti
o
n
 
a
t 
a
ll 
M
in
o
r 
c
o
n
tr
ib
u
ti
o
n
 
M
o
d
e
ra
te
 
c
o
n
tr
ib
u
ti
o
n
 
L
a
rg
e
 
c
o
n
tr
ib
u
ti
o
n
 
E
x
tr
e
m
e
ly
 
la
rg
e
 
c
o
n
tr
ib
u
ti
o
n
 
Number 
(%) of 
PRPs 
0 3 (50%) 2 (33%) 1 (17%) 0 
 
 
 
 
Q3. How much do you feel you have been able to contribute positively to WP4 
(dissemination & user integration)? 
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Q4. How well did you feel you understood the objectives, methods and outcomes 
of EuroTEAM? 
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Q5. How did you feel about the number of assignments for PRPs in EuroTEAM? 
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Q6. How did you feel about the level of difficulty of the assignments for PRPs in 
EuroTEAM? 
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Q7. How did you feel about the amount of information you received about 
assignments for PRPs in EuroTEAM? 
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Q8. How useful did you find the glossary for PRPs? 
 
 
N
o
t 
a
t 
a
ll 
u
s
e
fu
l 
N
o
t 
v
e
ry
 
u
s
e
fu
l 
M
o
d
e
ra
te
l
y
 u
s
e
fu
l 
V
e
ry
 
u
s
e
fu
l 
E
x
tr
e
m
e
ly
 
u
s
e
fu
l 
Number 
(%) of 
PRPs 
0 0 0 5 (83%) 1 (17%) 
 
 
Q9. How welcome did you feel your opinions were? 
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Q10. How well was PRP involvement co-ordinated? 
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Q11. How did you feel about the amount of feedback you received on the outcome 
of your contribution to assignments for PRPs? 
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Q12. How did you feel about how fairly your contributions to the EuroTEAM project 
have been acknowledged? 
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Q13. How well did you feel your contribution to EuroTEAM meetings was 
supported? 
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Q14. How interested are you in contributing to future research projects as a PRP? 
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Table 5. Quantitative results of the survey for researchers (N=15)  1 
 
Q1. How much experience of working with PRPs did you have before your 
involvement with EuroTEAM? 
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Q2a. Which WP have you been most involved with? 
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Q2b. How much do you feel that PRPs have been able to contribute positively to 
this WP? 
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Q3a. Which other WPs have you been involved with (if any)? 1  
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15 of the 15 respondents were involved with more than one work package 
 
Q3b. How much do you feel that PRPs have been able to contribute positively to 
this WP? 
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Q4. What kind of impact do you think PRP involvement has had on EuroTEAM 
overall? 
 
 
E
x
tr
e
m
e
ly
 
n
e
g
a
ti
v
e
 
im
p
a
c
t 
N
e
g
a
ti
v
e
 
im
p
a
c
t 
S
lig
h
tl
y
 
n
e
g
a
ti
v
e
 
im
p
a
c
t 
N
o
 i
m
p
a
c
t 
S
lig
h
tl
y
 
p
o
s
it
iv
e
 
im
p
a
c
t 
P
o
s
it
iv
e
 
im
p
a
c
t 
E
x
tr
e
m
e
ly
 
p
o
s
it
iv
e
 
im
p
a
c
t 
Number 
(%) of 
researchers 
0 0 0 0 
2 
(13.3%) 
6 
(40%) 
7 
(46.7%) 
 
 
Q5a. Did you have any practical experience of working with patients within 
EuroTEAM? 
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Number (%) of researchers 10 (66.7%) 5 (33.3%) 
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